A Randomised Control Trial to Establish if Use of the gekoTM (Trademark) Post Infra-inguinal Surgical Vein Revascularisation Increases Flow Through the Graft
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- Change in arterial blood volume flow in the bypass graft measured by ultrasound.
研究概览
简要总结
A study to investigate if the gekoTM device improves flow through vascular bypass grafts
详细描述
The geko™ device, (CE 558928;British Standards Institute notified body 0086), wearable, discrete, self-contained stimulation unit that adheres to the skin (see www.gekodevices.com). The, geko™ produces small electrical impulses that gently activate the common peroneal nerve within the popliteal fossa, behind the knee, in turn activating the venous muscle pumps of the calf and foot. Substantive increases in lower limb blood flow have been demonstrated to improve arterial, venous and microcirculatory blood flow with no reported morbidity.
RATIONALE Early infra-inguinal graft failure, i.e. occurring within 30 days of surgery occurs in approximately 5% of patients16. It is known that the predominant cause of this is thrombosis. The geko™ is an electrical device placed over the common peroneal nerve alongside the knee. The device activates muscle contraction in the peronei using low intensity, low frequency (1Hz) stimulation. The muscle contraction expresses blood from the deep venous system. Application of the stimulation device over the peroneal nerve is suitable for practical purposes. Previous studies have shown that the geko™ substantively increases arterial, venous and microcirculatory blood flow in healthy volunteers. A significant decrease in Tissue Plasminogen Activator antigen has also been demonstrated which indicates increased fibrinolytic activity3. Application of the geko™ device should therefore decrease stasis and increase flow though the graft and as such reduce the risk of thrombosis and as such graft failure.
Study:
Environmental Conditions The examinations will be carried out in a designated temperature controlled clinical room in the Vascular Lab at Hull Royal Infirmary. Participants will be required to abstain from vigorous exercise, nicotine, caffeine and fatty foods prior to their examination. They will be required to wear light garments with their legs exposed.
The geko™ device will be applied to outer/ posterior aspect of the knee whilst the subjects are semi-recumbent, with their knees flexed. The participants will be given 30 minutes in the quiet, environmentally controlled room prior to commencement of measurement to enable equilibration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years,
- •Undergoing infra-inguinal vein bypass graft.
- •Intact cutaneous sensations to nociception in the lower limb, as determined by the investigator.
- •Intact healthy skin at site of application.
- •On effective contraception if sexually active - oral contraceptive pill (> 3 months use), condoms, intrauterine contraceptive device, depot injection.
- •Able to understand the Patient Information Sheet and capable and willing to give informed consent and follow the protocol requirements
排除标准
- •History of haematological disorder or DVT within the preceding 6 months,
- •Pregnant or planning to become pregnant during study duration,
- •Pacemakers or implantable defibrillators,
- •Use of any other neuro-modulation device,
- •Current use of TENS in pelvic region, back or legs,
- •Use of investigational drug/device therapy within past 4 weeks that may interfere with this study,
- •Significant varicose veins or lower limb ulceration.
- •Recent surgery (such as abdominal, gynaecological, hip knee replacement).
- •Recent trauma to lower limbs.
- •Chronic Obesity (BMI Index >34).
- •Any medication judged to be significant by the Principal Investigator.
- •Any significant illness during the four (4) weeks preceding the screening period of the study.
研究组 & 干预措施
No intervention
No intervention
GekoTM
geko applied to bypass limb
干预措施: GekoTM (Device)
结局指标
主要结局
Change in arterial blood volume flow in the bypass graft measured by ultrasound.
时间窗: 1 day
Measured by ultrasound duplex
次要结局
- To assess effect on microcirculation(1 day)
- To assess effect on levels of VEGF, PAI-1 and tPA antigen.(1 day)
- To assess effect on blood flow in the superficial femoral vein(1 day)
- To assess effect on pulse wave velocity, cardiac output and stroke volume(1 day)
- To assess the impact of gekoTM device on pain score utilising the McGill Pain score(1 day)
- To assess effect on calf circumference(1 day)
- Patient tolerance/ acceptability(1 day)
